Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.

Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ.

Adv Radiat Oncol. 2019 Feb 19;4(2):314-322. doi: 10.1016/j.adro.2019.02.002. eCollection 2019 Apr-Jun.

2.

Corrigendum to "Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy" [Heliyon 4 (12) (December 2018) e01039].

Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Pham T, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H.

Heliyon. 2019 Mar 18;5(3):e01309. doi: 10.1016/j.heliyon.2019.e01309. eCollection 2019 Mar.

3.

Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence.

Wymer KM, Sharma V, Davis BJ, Kwon ED, Mynderse LA, Karnes RJ.

Clin Genitourin Cancer. 2019 Jun;17(3):e536-e540. doi: 10.1016/j.clgc.2019.01.019. Epub 2019 Feb 6. No abstract available.

PMID:
30902522
4.

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA.

Adv Radiat Oncol. 2018 Sep 5;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.

5.

Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy.

Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Orzechowski A, Pham T, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H.

Heliyon. 2018 Dec 18;4(12):e01039. doi: 10.1016/j.heliyon.2018.e01039. eCollection 2018 Dec. Erratum in: Heliyon. 2019 Mar 18;5(3):e01309.

6.

Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT.

Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):229-240. doi: 10.1016/j.ijrobp.2018.09.001. Epub 2018 Sep 8.

PMID:
30205124
7.

Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.

Sharma V, Nehra A, Colicchia M, Westerman ME, Kawashima A, Froemming AT, Kwon ED, Mynderse LA, Karnes RJ.

Eur Urol. 2018 Jun;73(6):879-887. doi: 10.1016/j.eururo.2017.11.012. Epub 2017 Nov 28.

PMID:
29195777
8.

Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39. doi: 10.1016/j.prro.2017.07.011. Epub 2017 Jul 20. Review.

9.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2018 Mar;199(3):726-733. doi: 10.1016/j.juro.2017.09.033. Epub 2017 Sep 12.

PMID:
28916273
10.

Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience.

Erie AJ, Morris JM, Welch BT, Kurup AN, Weisbrod AJ, Atwell TD, Schmit GD, Kwon ED, Callstrom MR.

J Vasc Interv Radiol. 2017 Jul;28(7):987-992. doi: 10.1016/j.jvir.2017.03.012. Epub 2017 Apr 21.

PMID:
28434661
11.

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS.

BMC Urol. 2017 Mar 21;17(1):19. doi: 10.1186/s12894-017-0209-3.

12.

Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.

Bhindi B, Rangel LJ, Mason RJ, Gettman MT, Frank I, Kwon ED, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.

J Urol. 2017 Jul;198(1):86-91. doi: 10.1016/j.juro.2017.01.063. Epub 2017 Jan 24.

PMID:
28130104
13.

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535. doi: 10.1016/j.ijrobp.2016.11.014. Epub 2016 Nov 17.

14.

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengeløv L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W.

J Clin Oncol. 2017 Jan;35(1):40-47. Epub 2016 Oct 31.

PMID:
28034081
16.

Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.

Sonpavde G, Pond GR, Templeton AJ, Kwon ED, De Bono JS.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):67-71. doi: 10.1038/pcan.2016.44. Epub 2016 Sep 27.

PMID:
27670718
17.

Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.

Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED.

Eur Urol. 2017 Mar;71(3):340-348. doi: 10.1016/j.eururo.2016.08.055. Epub 2016 Sep 3.

18.

Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with 11C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging.

Sobol I, Zaid HB, Haloi R, Mynderse LA, Froemming AT, Lowe VJ, Davis BJ, Kwon ED, Karnes RJ.

J Urol. 2017 Jan;197(1):129-134. doi: 10.1016/j.juro.2016.07.073. Epub 2016 Jul 20.

PMID:
27449262
19.

Prostate cancer post-treatment follow-up and recurrence evaluation.

May EJ, Viers LD, Viers BR, Kawashima A, Kwon ED, Karnes RJ, Froemming AT.

Abdom Radiol (NY). 2016 May;41(5):862-76. doi: 10.1007/s00261-015-0562-1. Review.

PMID:
27193788
20.

Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702. doi: 10.1016/j.ijrobp.2016.01.032. Epub 2016 Jan 29.

21.

Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup.

Moschini M, Sharma V, Zattoni F, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Kwon ED, Karnes RJ.

J Urol. 2016 Jun;195(6):1773-8. doi: 10.1016/j.juro.2015.12.074. Epub 2015 Dec 23.

PMID:
26723866
22.

Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma.

Gustafson MP, Lin Y, Bleeker JS, Warad D, Tollefson MK, Crispen PL, Bulur PA, Harrington SM, Laborde RR, Gastineau DA, Leibovich BC, Cheville JC, Kwon ED, Dietz AB.

Clin Cancer Res. 2015 Sep 15;21(18):4224-33. doi: 10.1158/1078-0432.CCR-15-0260. Epub 2015 May 21.

23.

Immunotherapy in prostate cancer.

Sobol I, Thompson RH, Dong H, Krco C, Kwon ED.

Curr Urol Rep. 2015 Jun;16(6):34. doi: 10.1007/s11934-015-0509-7. Review.

PMID:
25894495
24.

PD-1 Restrains Radiotherapy-Induced Abscopal Effect.

Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED.

Cancer Immunol Res. 2015 Jun;3(6):610-9. doi: 10.1158/2326-6066.CIR-14-0138. Epub 2015 Feb 19.

25.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

26.

Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography.

Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, Mynderse LA, Kwon ED.

J Urol. 2015 Jan;193(1):111-6. doi: 10.1016/j.juro.2014.08.082. Epub 2014 Aug 20.

PMID:
25150640
27.

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED.

J Thorac Oncol. 2014 Jul;9(7):1036-40. doi: 10.1097/JTO.0000000000000177.

28.

B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation.

Gibbons RM, Liu X, Harrington SM, Krco CJ, Kwon ED, Dong H.

Cancer Immunol Immunother. 2014 Aug;63(8):859-67. doi: 10.1007/s00262-014-1563-6. Epub 2014 Jun 4.

29.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR; CA184-043 Investigators.

Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.

30.

Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP, Cheville J, Kwon ED, Thompson EA, Parker A.

Cancer Immunol Res. 2013 Dec;1(6):378-85. doi: 10.1158/2326-6066.CIR-13-0042. Epub 2013 Aug 29.

31.

Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.

Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ.

Mayo Clin Proc. 2014 Mar;89(3):308-18. doi: 10.1016/j.mayocp.2013.12.001. Epub 2014 Jan 31.

PMID:
24486077
32.

Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.

Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H.

Oncoimmunology. 2013 Jun 1;2(6):e23972. Epub 2013 Jun 6.

33.

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.

Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC.

BJU Int. 2013 Jun;111(7):1046-53. doi: 10.1111/bju.12075. Epub 2013 Apr 2.

34.

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.

Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR.

Front Oncol. 2013 Jan 22;2:215. doi: 10.3389/fonc.2012.00215. eCollection 2012.

35.

Immune monitoring using the predictive power of immune profiles.

Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, Bauer PR, Abraham RS, Tollefson MK, Kwon ED, Gastineau DA, Dietz AB.

J Immunother Cancer. 2013 Jun 27;1:7. doi: 10.1186/2051-1426-1-7. eCollection 2013.

36.

B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim.

Gibbons RM, Liu X, Pulko V, Harrington SM, Krco CJ, Kwon ED, Dong H.

Oncoimmunology. 2012 Oct 1;1(7):1061-1073.

37.

Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment.

Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ.

J Urol. 2013 Apr;189(4):1308-13. doi: 10.1016/j.juro.2012.10.069. Epub 2012 Oct 30.

PMID:
23123372
38.

Potential role of genetic markers in the management of kidney cancer.

Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH, Oosterwijk E.

Eur Urol. 2013 Feb;63(2):333-40. doi: 10.1016/j.eururo.2012.09.040. Epub 2012 Sep 24. Review.

PMID:
23040205
39.

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, Aubry MC.

Clin Lung Cancer. 2013 Mar;14(2):157-63. doi: 10.1016/j.cllc.2012.05.006. Epub 2012 Aug 4.

PMID:
22868219
40.

Soluble B7-H1: differences in production between dendritic cells and T cells.

Frigola X, Inman BA, Krco CJ, Liu X, Harrington SM, Bulur PA, Dietz AB, Dong H, Kwon ED.

Immunol Lett. 2012 Feb 29;142(1-2):78-82. doi: 10.1016/j.imlet.2011.11.001. Epub 2011 Nov 25.

41.

B7-h1 expressed by activated CD8 T cells is essential for their survival.

Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H.

J Immunol. 2011 Dec 1;187(11):5606-14. doi: 10.4049/jimmunol.1003976. Epub 2011 Oct 24.

42.

Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED.

Clin Cancer Res. 2011 Apr 1;17(7):1915-23. doi: 10.1158/1078-0432.CCR-10-0250. Epub 2011 Feb 25.

43.

Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome.

Wada DA, Wilcox RA, Harrington SM, Kwon ED, Ansell SM, Comfere NI.

Am J Hematol. 2011 Mar;86(3):325-7. doi: 10.1002/ajh.21960. Epub 2011 Feb 15. No abstract available.

44.

Tissue microarrays: one size does not fit all.

Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED.

Diagn Pathol. 2010 Jul 7;5:48. doi: 10.1186/1746-1596-5-48.

45.

B7-H1 expression in vestibular schwannomas.

Archibald DJ, Neff BA, Voss SG, Splinter PL, Driscoll CL, Link MJ, Dong H, Kwon ED.

Otol Neurotol. 2010 Aug;31(6):991-7. doi: 10.1097/MAO.0b013e3181e40e4f.

46.

Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer.

Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1343-9. doi: 10.1016/j.ijrobp.2010.01.061. Epub 2010 Jul 2.

PMID:
20598810
48.

TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.

Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H.

J Immunol. 2009 Sep 15;183(6):3634-41. doi: 10.4049/jimmunol.0900974. Epub 2009 Aug 26.

49.

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM.

Blood. 2009 Sep 3;114(10):2149-58. doi: 10.1182/blood-2009-04-216671. Epub 2009 Jul 13.

50.

T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.

Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Leibovich BC, Kwon ED.

Urology. 2009 Dec;74(6):1359-64. doi: 10.1016/j.urology.2009.03.007. Epub 2009 Jun 7.

Supplemental Content

Support Center